ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00100555
Recruitment Status : Completed
First Posted : January 4, 2005
Last Update Posted : April 27, 2012
Sponsor:
Information provided by:
Novartis

Brief Summary:
The purpose of this trial is to study the clinical safety, tolerability, and efficacy of zoledronic acid compared to an oral bisphosphonate in postmenopausal women with osteoporosis.

Condition or disease Intervention/treatment Phase
Osteoporosis Drug: zoledronic acid Phase 3

Study Type : Interventional  (Clinical Trial)
Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate
Study Start Date : June 2004
Actual Primary Completion Date : June 2005
Actual Study Completion Date : June 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoporosis
U.S. FDA Resources




Primary Outcome Measures :
  1. Assess the rapidity of onset of action on bone turnover by comparing the percent change from baseline in urine N-telopeptide (NTx) in post-menopausal women

Secondary Outcome Measures :
  1. To assess the effect on markers of bone turnover by comparing the percent change from baseline in serum C-telopeptide (CTx) and urine NTx in post-menopausal women
  2. To assess the frequency, intensity, and "bothersomeness" of dyspepsia, as measured by the Nepean Dyspepsia Index - Short Form, Symptom Checklist
  3. To assess patient preferences for annual i.v. therapy compared to weekly oral therapy


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   45 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Postmenopausal women between 45 and 79 years of age
  • Must be osteopenic/osteoporotic

Exclusion Criteria:

  • Any women of child-bearing potential

Other protocol-defined inclusion/exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00100555


Locations
United States, Alabama
Univ. of Alabama/Division of Clinical Immunology and Rheumatology
Birmingham, Alabama, United States, 35294
United States, California
Radiant Research
San DIego, California, United States, 92108
United States, Colorado
Denver Arthritis Clinic
Denver, Colorado, United States, 80230
United States, Florida
Florida Medical Research Institute
Gainesville, Florida, United States, 32605
United States, Illinois
Northwestern Center for Clinical Research
Chicago, Illinois, United States, 60611
United States, Maryland
The Center for Rheumatology and Bone Research
Wheaton, Maryland, United States, 20902
United States, Michigan
Midwest Arthritis Center
Kalamazoo, Michigan, United States, 49048-1634
United States, Missouri
St. John's Medical Research
Springfield, Missouri, United States, 65807
United States, Montana
Deaconess Billings Clinic Research Division
Billings, Montana, United States, 59101
United States, New Jersey
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States, 08903
United States, New York
Helen Hayes Hospital - Regional Bone Clinic
West Haverstraw, New York, United States, 10993
United States, Ohio
Private Practice
Mayfield Village, Ohio, United States, 44143
United States, Tennessee
The Arthritis Clinic of Jackson
Jackson, Tennessee, United States, 38305
United States, Texas
Radiant Research
Dallas, Texas, United States, 75235
Univ. of North Texas Health Science Center at Fort Worth
Fort Worth, Texas, United States, 76107
St. Luke's Episcopal Hospital Ctr for Ortho. Res. and Education
Houston, Texas, United States, 77030
United States, Utah
Women's Health Center
Salt Lake City, Utah, United States, 84117
United States, West Virginia
Valley Medical Associates
Lewisburg, West Virginia, United States, 24901
Sponsors and Collaborators
Novartis Pharmaceuticals

ClinicalTrials.gov Identifier: NCT00100555     History of Changes
Other Study ID Numbers: CZOL446H2315
First Posted: January 4, 2005    Key Record Dates
Last Update Posted: April 27, 2012
Last Verified: April 2012

Keywords provided by Novartis:
Osteoporosis, osteopenia, post-menopausal, zoledronic acid

Additional relevant MeSH terms:
Osteoporosis
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Zoledronic acid
Diphosphonates
Bone Density Conservation Agents
Physiological Effects of Drugs